Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Bromhexine  COVID-19 treatment studies for Bromhexine  C19 studies: Bromhexine  Bromhexine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 91% Improvement Relative Risk Ventilation 89% ICU admission 82% c19early.org/b Ansarin et al. Bromhexine for COVID-19 RCT EARLY TREATMENT Is early treatment with bromhexine beneficial for COVID-19? RCT 78 patients in Iran Lower ventilation (p=0.014) and ICU admission (p=0.013) Ansarin et al., Bioimpacts, doi:10.34172/bi.2020.27 Favors bromhexine Favors control
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
Ansarin et al., Bioimpacts, doi:10.34172/bi.2020.27
Ansarin et al., Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial, Bioimpacts, doi:10.34172/bi.2020.27
Jul 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT with 39 bromhexine and 39 control patients showing lower mortality, intubation, and ICU admission with treatment. The treatment group received bromhexine hydrochloride 8 mg three times a day for two weeks. All patients received SOC including HCQ.
Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion.
risk of death, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 39 (0.0%), control 5 of 39 (12.8%), NNT 7.8, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 88.9% lower, RR 0.11, p = 0.01, treatment 1 of 39 (2.6%), control 9 of 39 (23.1%), NNT 4.9.
risk of ICU admission, 81.8% lower, RR 0.18, p = 0.01, treatment 2 of 39 (5.1%), control 11 of 39 (28.2%), NNT 4.3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ansarin et al., 19 Jul 2020, Randomized Controlled Trial, Iran, peer-reviewed, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBromhexineAll
Abstract: B BioImpacts Ansarin et al, BioImpacts, 2020, 10(4), 209-215 doi: 10.34172/bi.2020.27 http://bi.tbzmed.ac.ir/ TUOMS TUOMS PRESS PRESS Publish Free ccess Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial Khalil Ansarin1,2 , Ramin Tolouian3, Mohammadreza Ardalan4* , Ali Taghizadieh2,5, Mojtaba Varshochi6, Soheil Teimouri5, Tahere Vaezi5, Hamed Valizadeh2,5, Parviz Saleh4, Saeid Safiri7,8 , Kenneth R. Chapman9 ID ID ID ID Rahat Breath and Sleep Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 3 Division of Nephrology, University of Arizona, Tucson, AZ, USA 4 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 5 Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran 6 Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 7 Department of Community Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran 8 Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran 9 Asthma and Airway Center, University Health Network, University of Toronto, Toronto, ON, Canada 1 2 Article Info Article Type: Original Article Article History: Received: 7 July 2020 Revised: 16 July 2020 Accepted: 18 July 2020 ePublished: 19 July 2020 Keywords: Bromhexine hydrochloride COVID-19 disease SARS-CoV2 TMPRSS2 COVID-19 pneumonia COVID-19 treatment Abstract Introduction: Bromhexine is a potential therapeutic option in COVID-19, but no data from a randomized clinical trial has been available. The present study aimed to evaluate the efficacy of bromhexine in intensive care unit (ICU) admission, mechanical ventilation, and mortality in patients with COVID-19. Methods: An open-label randomized clinical trial study was performed in Tabriz, NorthWest of Iran. They were randomized to either the treatment with the bromhexine group or the control group, in a 1:1 ratio with 39 patients in each arm. Standard therapy was used in both groups and those patients in the treatment group received oral bromhexine 8 mg three times a day additionally. The primary outcome was a decrease in the rate of ICU admissions, intubation/ mechanical ventilation, and mortality. Results: A total of 78 patients with similar demographic and disease characteristics were enrolled. There was a significant reduction in ICU admissions (2 out of 39 vs. 11 out of 39, P = 0.006), intubation (1 out of 39 vs. 9 out of 39, P = 0.007) and death (0 vs. 5, P = 0.027) in the bromhexine treated group compared to the standard group. No patients were withdrawn from the study because of adverse effects. Conclusion: The early administration of oral bromhexine reduces the ICU transfer, intubation, and the mortality rate in patients with COVID-19. This affordable medication can easily be administered everywhere with a huge positive impact(s) on public health and the world economy. Altogether, the verification of our results on a larger scale and different medical centers is strongly recommended. Trial Registration: IRCT202003117046797N4; https://irct.ir/trial/46969.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit